These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27393396)

  • 1. Biosimilars: from Technical to Pharmacoeconomic Considerations.
    Girault D; Trouvin JH; Blachier-Poisson C; Gary F; Laloye D; ; Bergmann JF; Casadevall N; Delval C; De Sahb Berkovitch R; Fagon JY; Gersberg M; Lassale C; Lechat P; Le Jeunne C; Montastruc JL; Prugnaud JL; Ratignier-Carbonneil C; Rey-Coquais C
    Therapie; 2015; 70(1):47-55. PubMed ID: 27393396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars: from technical to pharmacoeconomic considerations. 30th Rencontres Nationales de Pharmacologie et Recherche clinique pour l'Innovation et l'Evaluation des Technologies de Santé. Tables rondes.
    Girault D; Trouvin JH; Blachier-Poisson C; Gary F; Laloye D; ; Bergmann JF; Casadevall N; Delval C; De Sahb Berkovitch R; Fagon JY; Gersberg M; Lassale C; Lechat P; Le Jeunne C; Montastruc JL; Prugnaud JL; Ratignier-Carbonneil C; Rey-Coquais C;
    Therapie; 2015; 70(1):37-55. PubMed ID: 25679193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars in psoriasis: what can we expect?
    Radtke MA; Augustin M
    J Dtsch Dermatol Ges; 2014 Apr; 12(4):306-12. PubMed ID: 24698590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biosimilars, no generic biologicals!].
    Knuts B
    J Pharm Belg; 2016 Dec; (4):24-29. PubMed ID: 30281245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologicals and biosimilars: safety issues in Europe.
    Portela MDCC; Sinogas C; Albuquerque de Almeida F; Baptista-Leite R; Castro-Caldas A
    Expert Opin Biol Ther; 2017 Jul; 17(7):871-877. PubMed ID: 28540760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biosimilars, the journey has begun].
    Martos-Rosa A; Martínez-de la Plata JE; Morales-Molina JA; Fayet-Pérez A; Acosta-Robles PJ
    Farm Hosp; 2015 Mar; 39(2):114-7. PubMed ID: 25817091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: Hope and concern.
    Emmanouilides CE; Karampola MI; Beredima M
    J Oncol Pharm Pract; 2016 Aug; 22(4):618-24. PubMed ID: 26391898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The advent of biosimilars for the treatment of diabetes: current status and future directions.
    Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP
    Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are biosimilars really generics?
    Misra A
    Expert Opin Biol Ther; 2010 Apr; 10(4):489-94. PubMed ID: 20146636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars: how similar or dissimilar are they?
    Roger SD
    Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars in oncology: from development to clinical practice.
    Rak Tkaczuk KH; Jacobs IA
    Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007.
    Joung J; Robertson JS; Griffiths E; Knezevic I;
    Biologicals; 2008 Jul; 36(4):269-76. PubMed ID: 18218324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars: pharmacovigilance and risk management.
    Zuñiga L; Calvo B
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: Concepts and controversies.
    Gámez-Belmonte R; Hernández-Chirlaque C; Arredondo-Amador M; Aranda CJ; González R; Martínez-Augustin O; Sánchez de Medina F
    Pharmacol Res; 2018 Jul; 133():251-264. PubMed ID: 29428205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioanalytical challenges of biosimilars.
    Islam R
    Bioanalysis; 2014 Feb; 6(3):349-56. PubMed ID: 24471955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.